A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2015
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Feb 2008 Status changed from recruiting to in progress.